Showing 3271-3280 of 3597 results for "".
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Estée Lauder Companies Anti-Aging Research On Skin Demonstrates Efficacy of Actives and Novel Technologies in Skin Researchhttps://practicaldermatology.com/news/este-lauder-companies-anti-aging-research-on-skin-demonstrates-efficacy-of-actives-and-novel-technologies-in-skin-research/2457874/The Estée Lauder Companies Research & Development (R&D) presented research focused on new findings in anti-aging skin research at the 2018 American Academy of Dermatology Annual Meeting in San Diego. The following reserach was presented at poster presentations at the AAD me
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an ass
- Stelara Reduces Aortic Vascular Inflammationhttps://practicaldermatology.com/news/stelara-reduces-aortic-vascular-inflammation/2457880/In addition to its effects on skin inflammation, Stelara (Ustekinumab) reduces aortic inflammation, report researchers from the Perelman School of Medicine at the University of Pennsylvania at the annual meeting of the American Academy of Dermato
- Merkel Cell Carcinoma Is On The Risehttps://practicaldermatology.com/news/merkel-cell-carcinoma-is-on-the-rise/2457879/Merkel cell carcinoma (MCC) is on the rise, according to new research published in the Journal of the American Academy of Dermatology and presented at the American Academy of Dermatology 2018 Annual Meetin
- Allergan Rolls Out "Not Cool vs. Cool"CoolSculpting Campaign Starring Professional Male Athlete Brand Ambassadorshttps://practicaldermatology.com/news/allergan-rolls-out-not-cool-vs-coolcoolsculpting-campaign-starring-professional-male-athlete-brand-ambassadors/2457905/Allergan’s new "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® stars Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Go
- Eyelid SCC On the Rise in Englandhttps://practicaldermatology.com/news/eyelid-scc-on-the-rise-in-england/2457911/Cases of a squamous cell carcinoma (SCC) in the eyelids is on the rise in England, according to new research in the British Journal of Ophthalmology. Specifically, there has been an annual increase
- New AD Yardstick Highlights Treatment Advanceshttps://practicaldermatology.com/news/new-ad-yardstick-highlights-treatment-advances/2457933/Treatment for atopic dermatitis (AD) has changed a lot in the last few years, according to a new yardstick published in Annals of Allergy, Asthma and Immunology. “The Atopic Dermatitis Yardstick
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil
- UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-bimekizumab-shows-joint-and-skin-responses-in-psoriatic-arthritis/2457945/UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy in psor